Abstract

Mast cells are tissue-resident immune cells that function in both innate and adaptive immunity through the release of both preformed granule-stored mediators, and newly generated proinflammatory mediators that contribute to the generation of both the early and late phases of the allergic inflammatory response. Although mast cells can be activated by a vast array of mediators to contribute to homeostasis and pathophysiology in diverse settings and contexts, in this review, we will focus on the canonical setting of IgE-mediated activation and allergic inflammation. IgE-dependent activation of mast cells occurs through the high affinity IgE receptor, FcεRI, which is a multimeric receptor complex that, once crosslinked by antigen, triggers a cascade of signaling to generate a robust response in mast cells. Here, we discuss FcεRI structure and function, and describe established and emerging roles of the β subunit of FcεRI (FcεRIβ) in regulating mast cell function and FcεRI trafficking and signaling. We discuss current approaches to target IgE and FcεRI signaling and emerging approaches that could target FcεRIβ specifically. We examine how alternative splicing of FcεRIβ alters protein function and how manipulation of splicing could be employed as a therapeutic approach. Targeting FcεRI directly and/or IgE binding to FcεRI are promising approaches to therapeutics for allergic inflammation. The characteristic role of FcεRIβ in both trafficking and signaling of the FcεRI receptor complex, the specificity to IgE-mediated activation pathways, and the preferential expression in mast cells and basophils, makes FcεRIβ an excellent, but challenging, candidate for therapeutic strategies in allergy and asthma, if targeting can be realized.

Highlights

  • Publisher’s Note: MDPI stays neutralChronic allergic diseases affect approximately 300 million people worldwide [1], and are often the result of inappropriate, detrimental immune responses to typically harmless environmental antigens

  • An important population are mast cells, which play a key role in triggering the immediate allergic response and likely drive allergic inflammation through direct interactions with immunoglobulin E (IgE)

  • By determining the various roles of MS4A2 splice variants in mast cells, it becomes apparent that alternative splicing of FcεRIβ pre-mRNA selectively removes domains in the protein that are critical for specific functions

Read more

Summary

Introduction

Chronic allergic diseases affect approximately 300 million people worldwide [1], and are often the result of inappropriate, detrimental immune responses to typically harmless environmental antigens. Chronic allergic diseases have complex pathophysiology involving interactions between many immune cells Of these cells, an important population are mast cells, which play a key role in triggering the immediate allergic response and likely drive allergic inflammation through direct interactions with immunoglobulin E (IgE). Binding of IgE to FcεRI results in surface IgE that persist on mast cells for prolonged periods, likely contributing to the calculated half-life of IgE in tissues being much greater than blood (16–20 days) [9]. Allergic response by initiating the synthesis and secretion of proinflammatory cytokines and chemokines, which recruit and activate other key inflammatory effector cells, such as eosinophils and T cells (reviewed in [7,13])

FcεRI Structure and Function
Existing Treatments Targeting FcεRI and IgE
Alternative Splicing of FcεRIβ and the Functions of Splice Variants
Functional Outcomes of Modulating FcεRIβ Expression in Mast Cells
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call